445PDDurability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

AbstractBackgroundGenomic rearrangements involving NTRK1/2/3 result in constitutively active TRK fusion proteins that are oncogenic drivers in multiple pediatric and adult cancers. Larotrectinib is a selective TRK inhibitor approved by the FDA in 2018 for the treatment of any TRK fusion cancer based on a primary analysis in 55 patients from 3 clinical trials [Drilon et al. NEJM 2018]. For the first time, we now report median duration of response (DOR) data in this primary cohort, as well as updated data in an expanded cohort of 159 total TRK fusion patients treated with larotrectinib, with 153 (55 primary + 98 supplemental) evaluable for efficacy.MethodsPatients with TRK fusion cancer detected by local molecular profiling were treated with larotrectinib across 3 studies (NCT02122913, NCT02637687, and NCT02576431). Disease status was assessed by investigators using RECIST 1.1. Data cut-off was 19 February 2019.ResultsIn the primary cohort of 55 patients with a median follow-up of 26 months, the median DOR in 44 patients with complete or partial responses was 35.2 months (95% CI 21.2 –NE), with 17 progression events and 27 responses ongoing (range 1.6–44 months). The median PFS in the primary cohort was 25.8 months (95% CI 9.9–NE), with 27 patients having progressed. In the expanded combined dataset, the most common tumor types included soft tissue sarcoma (n = 36), in fantile fibrosarcoma (n = 29), thyroid carcinoma (n =&thi...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: November 2020Source: Urology Case Reports, Volume 33Author(s): Gina T. Baaklini, Misty J. Thompson, Kevin J. Krauland, Daniel R. Walker, Steven J. Hudak
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 11 July 2020Source: European UrologyAuthor(s): Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 11 July 2020Source: European UrologyAuthor(s): Roderick C.N. van den Bergh, Olivier Rouvière, Theodorus van der Kwast, Erik Briers, Thomas Van den Broeck, Philip Cornford, Marcus G. Cumberbatch, Maria De Santis, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Nikolaos Grivas, Jeremy Grummet, Thomas B. Lam, Michael Lardas, Matthew Liew, Lisa Moris, Malcolm D. Mason, Nicolas Mottet, Daniela E. Oprea-Lager
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 11 July 2020Source: European Journal of Surgical OncologyAuthor(s): Xin Chen, Xingyu Feng, Muqing Wang, Xueqing Yao
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: Available online 10 July 2020Source: Pathology - Research and PracticeAuthor(s): Yiyang Bai, Jia Hou, Xiao Wang, Luying Geng, Xiaohui Jia, Luochengling Xiang, Kejun Nan
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 10 July 2020Source: Gynecologic Oncology ReportsAuthor(s): McKayla J. Riggs, Miranda Lin, Joseph Kim, Prakash Pandalai, Charles Dietrich
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Publication date: Available online 10 July 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Caterina Bonfiglio, Carla Maria Leone, Liciana Vaz de Arruda Silveira, Rocco Guerra, Giovanni Misciagna, Maria Gabriella Caruso, Irene Bruno, Claudia Buongiorno, Angelo Campanella, Vito Maria Bernardo Guerra, Maria Notarnicola, Valentina Deflorio, Isabella Franco, Antonella Bianco, Antonella Mirizzi, Laura Rosana Aballay, Anna Maria Cisternino, Paolo Sorino, Pasqua Letizia Pesole, Alberto Rubén Osella
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Authors: Śnietura M, Brewczynski A, Waniczek D, Kopec A, Stanek-Widera A, Muc-Wierzgoń M, Rutkowski T PMID: 32643355 [PubMed - in process]
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research
Publication date: Available online 11 July 2020Source: Medical Journal Armed Forces IndiaAuthor(s): Nikita Naredi, Pankaj Talwar, Sandeep Karunakaran
Source: Medical Journal Armed Forces India - Category: General Medicine Source Type: research
Publication date: Available online 11 July 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Tsung-Hao Liu, Yu-Yun Shao, Chih-Hung Hsu
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
More News: AstraZeneca | Biotechnology | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Employment | Fibrosarcoma | Genetics | Grants | Legislation | Lung Cancer | Merck | Pediatrics | Pfizer | Pharmaceuticals | Sarcomas | Soft Tissue Sarcoma | Study | Thyroid | Thyroid Cancer